ABC Farma - Artificial Intelligence Doctor
The decision by Abbott researchers and engineers to define a programmable pacing output range between 1.5 volts and 6.0 volts for the Aveir VR leadless pacemaker is the result of a precise balance between cardiac physiology, electrode–tissue physics, battery engineering, electrochemical safety, and long-term clinical reliability.
In most patients, ventricular capture thresholds cluster well below 1.5 V under stable conditions. However, myocardial excitability is dynamic and influenced by autonomic tone, circadian variation, electrolyte shifts, ischemia, fibrosis, medications, and aging tissue.
Setting the lower boundary near 1.5 V ensures consistent capture across nearly all physiologic conditions while maintaining a conservative safety margin above transient threshold fluctuations. Values below this level risk intermittent non-capture in real-world myocardium.
Unlike transvenous systems, leadless pacemakers deliver energy directly through a compact fixation helix embedded in ventricular myocardium. This creates high current density at the electrode–tissue interface, making capture sensitive to subtle changes in impedance, encapsulation, or local fibrosis.
An upper programmable limit of 6.0 V allows clinicians to overcome temporary or progressive increases in capture threshold without violating electrochemical safety constraints.
Pacing energy consumption scales approximately with the square of voltage. Increasing output from 1.5 V to 6.0 V represents roughly a sixteen-fold increase in energy expenditure.
Abbott therefore designed the system to support high outputs when necessary, while encouraging chronic programming near the capture threshold to preserve device longevity and battery stability.
Excessive pacing voltages risk irreversible electrode polarization, tissue injury, and water electrolysis at the electrode surface. Empirical and regulatory safety limits define a voltage ceiling below which charge delivery remains reversible and biocompatible.
The 6.0 V upper limit sits safely below these electrochemical risk thresholds while remaining clinically effective.
Clinicians expect modern pacemakers to support a familiar and flexible voltage range that accommodates diverse patient populations and disease states. A narrower range would increase the likelihood of revision, retrieval, or re-implantation—especially problematic in leadless systems.
Abbott’s 1.5 V–6.0 V output range represents the optimal intersection of myocardial physiology, leadless electrode physics, battery longevity, electrochemical safety, and real-world clinical use.
Below 1.5 V, capture reliability degrades. Above 6.0 V, safety margins and battery integrity are compromised. The selected range ensures durable pacing performance across the full lifespan of the Aveir VR system.